scholarly journals Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile

2021 ◽  
Vol 11 (8) ◽  
pp. 773
Author(s):  
Valentina Leta ◽  
Haidar S. Dafsari ◽  
Anna Sauerbier ◽  
Vinod Metta ◽  
Nataliya Titova ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Patient Specific ◽  
Motor Symptoms ◽  
Exclusion Criteria ◽  
Subcutaneous Infusion ◽  
Beneficial Effects ◽  
Advanced Therapies ◽  
Non Motor Symptoms

Device-aided therapies, including levodopa-carbidopa intestinal gel infusion, apomorphine subcutaneous infusion, and deep brain stimulation, are available in many countries for the management of the advanced stage of Parkinson’s disease (PD). Currently, selection of device-aided therapies is mainly focused on patients’ motor profile while non-motor symptoms play a role limited to being regarded as possible exclusion criteria in the decision-making process for the delivery and sustenance of a successful treatment. Differential beneficial effects on specific non-motor symptoms of the currently available device-aided therapies for PD are emerging and these could hold relevant clinical implications. In this viewpoint, we suggest that specific non-motor symptoms could be used as an additional anchor to motor symptoms and not merely as exclusion criteria to deliver bespoke and patient-specific personalised therapy for advanced PD.

scholarly journals The New Satisfaction with Life and Treatment Scale (SLTS-7) in Patients with Parkinson’s Disease

2021 ◽  
pp. 1-12
Author(s):  
Anna Sauerbier ◽  
Pia Bachon ◽  
Leire Ambrosio ◽  
Philipp A. Loehrer ◽  
Alexandra Rizos ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Factor Analysis ◽  
Exploratory Factor Analysis ◽  
Treatment Satisfaction ◽  
Satisfaction With Life ◽  
Motor Symptoms ◽  
Advanced Therapies ◽  
Non Motor Symptoms

Background: The satisfaction with life and, in particular, with treatment in Parkinson’s disease (PD) is understudied. Objective: To explore a new 7-item rating tool assessing satisfaction with life and treatment (SLTS-7) in PD. Methods: In this cross-sectional, multi-center study, including patients screened for advanced therapies, psychometric characteristics of the SLTS-7 were analyzed. An exploratory factor analysis identified the underlying factorial structure of the SLTS-7. Results: 117 patients were included, and the data quality of the SLTS-7 was excellent (computable data 100%), and acceptability measures satisfied standard criteria. Besides the global assessment (item 1), the exploratory factor analysis produced item 2 (physical satisfaction) as an independent item and two factors among the remaining items: items 3–5 (psycho-social satisfaction), and items 6 and 7 (treatment satisfaction). Cronbach’s alpha was 0.89, indicative of high internal consistency. The SLTS-7 total score correlated moderately with motor symptoms and weakly with non-motor symptoms total scores. SLTS-7 showed the highest correlations with the European Quality of Life with 5 items (EQ-5D) visual analog scale (0.43–0.58, p <  0.01), indicating a moderate convergent validity. The SLTS-7 significantly increased with higher non-motor symptoms burden levels (p = 0.002). Conclusion: Life satisfaction in PD covers three specific aspects, namely physical, psycho-social, and treatment satisfaction. The new SLTS-7 is a valid, reliable, and easy-to-use tool to assess satisfaction with life and treatment in patients with PD screened for advanced therapies. Longitudinal studies analyzing the effect of advanced PD treatment on life and treatment satisfaction are warranted.

scholarly journals Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease

2016 ◽  
Vol 9 (1) ◽  
pp. 78-85 ◽  
Author(s):  
Haidar Salimi Dafsari ◽  
Prashanth Reddy ◽  
Christiane Herchenbach ◽  
Stefanie Wawro ◽  
Jan Niklas Petry-Schmelzer ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Symptoms ◽  
Beneficial Effects ◽  
Subthalamic Stimulation ◽  
Non Motor Symptoms

The Role of Inflammatory Cytokines in Cognition and Other Non-Motor Symptoms of Parkinson’s Disease

2010 ◽  
Vol 51 (6) ◽  
pp. 474-479 ◽  
Author(s):  
Matthew Menza ◽  
Roseanne DeFronzo Dobkin ◽  
Humberto Marin ◽  
Margery H. Mark ◽  
Michael Gara ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Inflammatory Cytokines ◽  
Motor Symptoms ◽  
Non Motor Symptoms

scholarly journals Clinical and pathophysiological aspects of non-motor manifestations of Parkinson's disease

2020 ◽  
Vol 18 (4) ◽  
pp. 222-232
Author(s):  
M. A. Nikitina ◽  
N. G. Zhukova ◽  
E. Yu. Bragina ◽  
V. M. Alifirova ◽  
I. A. Zhukova ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Picture ◽  
Motor Symptoms ◽  
Correct Treatment ◽  
Neurodegenerative Process ◽  
Wide Range ◽  
Anxiety Depression ◽  
Non Motor Symptoms

Non-motor symptoms are an essential manifestation of the clinical picture of Parkinson's disease (PD). This literature review is devoted to the study of recent advances in the field of clinical and pathophysiological aspects of the non-motor manifestations of Parkinson's disease.Aim. The aim was to study and generalize the wide range of non-motor manifestations of PD and their features in this pathology, and to reveal the pathophysiological link between motor and non-motor manifestations of the disease and the role of the neurodegenerative process in the clinical picture of PD.Materials and methods. Keywords (Parkinson's disease, non-motor symptoms, apathy, anxiety, depression, sleep disorder, pain) search in the Web of Science, Core Collection, Scopus, Pubmed databases.Results. Knowledge about the presence of PD non-motor symptoms, characteristics of their manifestations improve their diagnosis and help to choose the correct treatment strategy. This survey comprises nonmotor manifestations of PD, such as: mood disorders (apathy, anxiety, depression), impulse control disorders (dopamine disregulation syndrome), sleep disorders (insomnia, excessive daytime sleepiness, bouts of sleepiness, conduct disorder in REM phase of sleep), autonomic disorders (constipation, enuresis, thermoregulatory dysfunction, cardiovascular disorders, orthostatic hypotension), and cognitive impairment. 

scholarly journals Microbiota and Parkinson's disease (overview)

2020 ◽  
pp. 10-14
Author(s):  
R. R. Tyutina ◽  
A. A. Pilipovich ◽  
V. L. Golubev ◽  
Al. B. Danilov
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nervous System ◽  
Substantia Nigra ◽  
Subsequent Development ◽  
Alpha Synuclein ◽  
Intestinal Wall ◽  
Motor Symptoms ◽  
Non Motor Symptoms

Parkinson's disease (PD) is characterized by both motor (hypokinesia, resting tremor, rigidity, postural instability) and non-motor symptoms. It is known that some non-motor manifestations, such as disturbances in smell, sleep, depression, gastrointestinal dysfunction, and others, may precede motor symptoms. Replenishment of dopamine deficiency, which, as known, develops in PD due to the death of dopaminergic neurons of the substantia nigra, makes it possible to influence most motor and some non-motor symptoms of parkinsonism, however many non-motor manifestations remain resistant to this therapy. In addition, it has only a symptomatic effect, and the pathogenetic treatment of PD is currently unavailable, which is primarily due to insufficient knowledge about the etiology and mechanisms of the development of the disease. In particular, it has already been established that alpha synuclein (a pathomorphological marker of PD) begins to be deposited in the intestinal wall, in the enteric nervous system (ENS) long before it appears in neurons of the substantia nigra. Understanding the mechanism of interaction along the axis “intestine – brain”, the role of intestinal wall dysfunction in the onset and development of PD can lead to the development of new directions in the treatment of this disease. Today, the role of microbiota, in particular the intestinal microbiota, in the functioning of the human body, its various systems, including the nervous system, is widely studied in the world. The influence of its imbalance on the activation of inflammatory reactions in the ENS and the possibility of the subsequent development of PD are considered. This review provides some evidence supporting the hypothesis that PD can be initiated in the gut. In addition, the possibilities of influencing the course of BP using pre-, pro-, syn- and metabiotics are considered.

Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease

2021 ◽  
Vol 34 (4) ◽  
pp. 263-273
Author(s):  
Mohammad Al Majali ◽  
Michael Sunnaa ◽  
Pratap Chand
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disorder ◽  
Review Article ◽  
Treatment Goals ◽  
Motor Symptoms ◽  
Adequate Treatment ◽  
Advanced Therapies ◽  
Non Motor Symptoms

Parkinson’s disease (PD) is the second commonest neurodegenerative disorder in the older adult and is characterized by progressive disabling motor symptoms of bradykinesia, tremor, rigidity, postural instability and also non motor symptoms that affect quality of life. The pharmacotherapy of PD consists of oral, transdermal, and subcutaneous medications, as well as invasive advanced therapies at later stages of the disease. PD medications are often started as monotherapy but with the progression of the illness often there is a need to add more medications and frequently comprises of a challenging polypharmacotherapy. Adverse effects of pharmacotherapy often add to the problems of adequate treatment. Patients and physicians have to prioritize treatment goals on the most disabling symptoms and the safest and most effective treatments. Almost every year newer medications and modes of delivery continue to be researched and added to the therapeutic armamentarium. This review article outlines existing and emerging pharmacotherapies for motor symptoms in PD.

Sign in / Sign up

Export Citation Format

Share Document